Company: HCWB
Filing Date: 2025-08-15
Form Type: NT 10-Q
Source: 0001193125-25-181394
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-08-15
Form: NT 10-Q
Chunk 0
---
? ☒ Yes ☐ No                                                                                                                                                                                        |     |            |     |                   |
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. In Q2 2024, HCW Biologics Inc.                   
 was involved in preparation and hearings for a long-running arbitration, which was settled shortly after Q2 2024 on July 13, 2024. Legal fees incurred by HCW Biologics Inc. in Q2 2024 were $10.4 million versus $142,452 in the same period 
 in 2025.                                                                                                                                                                                                                                      |     |                                                                                                                                                                                                                    |     |            |     |                   |

HCW Biologics Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: |     | August 15, 2025 |     | By: |     | /s/ Rebecca Byam        |
|:------|:----|:----------------|:----|:----|:----|:------------------------|
|       |     |                 |     |     |     | Rebecca Byam            |
|       |     |                 |     |     |     | Chief Financial Officer |